Risks
4 risks
Risk Intelligence
Sluggish Anti-Infective Season
View Risks →Alkem Laboratories Limited — Q4 FY24
Alkem Laboratories reported Q4 FY24 PAT of INR 294 crore, impacted by a deferred tax derecognition of INR 120 crore.
bullish
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem Laboratories reported Q4 FY24 PAT of INR 294 crore, impacted by a deferred tax derecognition of INR 120 crore. EBITDA margin improved 150 bps YoY to 13.7%, driven by lower raw material costs and stable US price erosion. Domestic business saw a rare YoY decline due to a high base in anti-infectives and channel normalization, but management expects a rebound with ~10% revenue growth in FY25, led by volume. The US business grew over 10% in FY24, with price erosion stabilizing at low single digits. International revenue crossed INR 4,000 crore for the first time. Key investments include a US CDMO facility for biosimilars (CapEx INR 600-700 crore) and R&D spend rising to 4.5-5%. Risks include sluggish anti-infective seasonality and potential raw material cost inflation.
अल्केम लैबोरेटरीज ने चौथी तिमाही में 294 करोड़ रुपये का मुनाफा कमाया, लेकिन 120 करोड़ रुपये का टैक्स एडजस्टमेंट हुआ। कंपनी की कमाई पर खर्च का अनुपात (EBITDA मार्जिन) 13.7% रहा, जो पिछले साल से 1.5% बेहतर है। इसकी वजह कच्चे माल की कम कीमत और अमेरिका में दवाओं के दाम स्थिर रहना है। भारत में बिक्री पिछले साल के मुकाबले कम रही, क्योंकि एंटी-इंफेक्टिव दवाओं की मांग घटी और बाजार सामान्य हुआ। लेकिन कंपनी को उम्मीद है कि अगले साल बिक्री 10% बढ़ेगी। अमेरिका में बिक्री 10% से ज्यादा बढ़ी और अंतरराष्ट्रीय कारोबार पहली बार 4,000 करोड़ रुपये पार कर गया। कंपनी बायोसिमिलर बनाने के लिए 600-700 करोड़ रुपये का नया प्लांट लगा रही है और रिसर्च पर खर्च बढ़ाकर 5% करेगी। जोखिम में एंटी-इंफेक्टिव दवाओं की कम मांग और कच्चे माल की कीमत बढ़ना शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Business Growth (FY24)
>10%
+10% YoY
US business reported double-digit growth for the full year, driven by stable pricing and volume.
International Revenue (FY24)
INR 4,000 Cr
First time crossing INR 4,000 Cr
International business crossed INR 4,000 crore in revenue for FY24, a milestone.
Cash Position
INR 3,550 Cr
Generated ~INR 1,400 Cr cash in FY24
Net cash position of ~INR 3,550 crore, reinforcing balance sheet strength.
Chronic Portfolio Contribution
17-18%
Expected to cross 20% in near term
Chronic portfolio contribution to domestic business is improving, targeting 20%+.
What Changed vs Last Quarter
NEW
FY25 Revenue Growth ~10%
Management expects overall revenue growth of around 10% in FY25, driven by domestic volume growth and stable US business.
NEW
EBITDA Margin to Remain at Current Levels
EBITDA margin expected to be in line with FY24 levels (~17.7%), with potential 20-30 bps improvement but offset by investments.
NEW
CapEx of INR 600-700 Cr in FY25
Total CapEx for FY25 is guided at INR 600-700 crore, including ~INR 400 crore for the US CDMO facility and INR 80-100 crore maintenance.
NEW
R&D Spend to Rise to 4.5-5%
R&D expenditure is expected to increase from 4.1% in FY24 to 4.5-5% of revenue in FY25, driven by biosimilar clinical trials.
DROPPED
Full-year EBITDA margin guidance of ~17%
Management expects FY24 EBITDA margin around 17%, with Q4 seasonally weaker but sustainable at that level.
DROPPED
Annual margin improvement of 50-100bps
Management reiterated internal target of 50-100bps annual EBITDA margin improvement going forward.
DROPPED
Enzene biosimilar breakeven this year
Biosimilar subsidiary Enzene expected to achieve breakeven in FY24 with revenue run-rate of ~₹200 Cr.
DROPPED
US facility CapEx of ~₹250 Cr for Enzene
Company investing ~₹250 Cr in a US biosimilar CDMO facility, expected to be operational in 2-3 years.
NEW RISK
Sluggish Anti-Infective Season
Q4 domestic decline was partly due to a weak anti-infective season; if FY25 monsoon is poor, acute portfolio growth may underperform.
NEW RISK
Raw Material Cost Inflation
While API prices are stable, any black swan event could increase costs; Pen G price decline has not materialized as expected.
NEW RISK
US Supply Chain Penalties
Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.
NEW RISK
Baddi Site FDA Observations
Baddi site received 10 observations from US FDA; though management downplayed, any escalation could delay approvals.
RISK GONE
Q4 seasonality and anti-infective dependency
Q4 historically weak due to seasonality and high anti-infective exposure, which could pressure margins.
RISK GONE
US biosimilar facility execution risk
Analyst questioned rationale for US facility given past St. Louis closure and competitive biosimilar landscape; management acknowledged learnings but remains confident.
RISK GONE
Red Sea freight cost impact
Rising freight costs due to Red Sea disruptions could impact export margins; management sees manageable impact unless spike worsens.
RISK GONE
Tax rate normalization post-FY26
Tax holidays for Sikkim facility end in FY26, potentially raising effective tax rate from 10-12% to 20-25%.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q3 FY24
Management expects FY24 EBITDA margin around 17%, with Q4 seasonally weaker but sustainable at that level.
Fast read
Guidance and risk preview
Management expects overall revenue growth of around 10% in FY25, driven by domestic volume growth and stable US business.
Q4 domestic decline was partly due to a weak anti-infective season; if FY25 monsoon is poor, acute portfolio growth may underperform.
View Risks →